Genezen is attending the ESGCT conference in Hamburg from October 27 to 30.

Founded in 2014 in Indianapolis, IN, Genezen is a best-in-class gene therapy CDMO with over a decade of experience supporting the cell and gene therapy manufacturing market worldwide. With capabilities across vector-modalities (AAV, lentiviral, retroviral, and others), Genezen partners with innovator organizations to deliver potentially life-saving gene and cell therapies – from concept to commercial. With flexible and customer-centric programs, Genezen tailors its partnership-model approach to all sizes and stages of organizations, to make viral vector production accessible to both early-stage, growth-oriented companies and established industry leaders. Genezen’s state-of-the art Lexington, MA site holds multiple global regulatory licenses, including with the FDA, EMA, Health Canada, and MFDS Korea, in support of the active manufacture of a commercial viral vector-based product. Our Indianapolis, IN site provides cGMP manufacturing for viral vectors and is currently supporting a program entering a pivotal clinical trial.